Intimation of Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

APTUS PHARMA LIMITED Date: 23rd October 2026 The BSE Ltd Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400001 SECURITY CODE: 544529 SCRIPT SYMBOL: APPL Sub: Intimation of Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam, Please find enclosed herewith the investor presentation on the financial results of the Company for the half year ended 30th September, 2026. The presentation is also being uploaded on the website of the company i.e. www.aptus- pharma.com You are requested to kindly take the above information on your records. Thanking you, Yours faithfully For Aptus Pharma Limited Tejash Maheshchandra Hathi Managing Director DIN: 03151221 Encl.: Investor Presentation Regd. Address: Ashutosh Buildcon, Opp. Slok – 2, Nr. Harikrupa Logistic Park, Aslali, Daskroi, Ahmedabad, Gujarat – 382427, India Contact: 76004 27827, E-mail: aptuspharma@rediffmail.com, Website: www.aptus-pharma.com CIN: U24230GJ2010PLC061957, GSTIN: 24AAICA7890D1ZM INVESTOR PRESENTATION Disclaimer & Forward-Looking Statements This Investor Presentation has been prepared by Aptus Pharma Limited (“the Company”) for general information purposes only. The information contained herein is based on the Company's records, management estimates, current expectations and assumptions and is subject to change without notice. The financial information presented herein for the half-year ended 30th September, 2026 is based on the financial results prepared in accordance with the applicable Accounting Standards (AS) prescribed under the Companies (Accounting Standards) Rules, 2021, and the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Certain statements in this presentation, including those relating to future business plans, expansion, growth prospects, strategies, projections and business outlook, may constitute forward-looking statements. Such statements are based on management's current expectations and assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied. Accordingly, no assurance can be given that such expectations or plans will be realised. This presentation does not constitute an offer, invitation or recommendation to buy, sell or hold any securities of the Company and should not be relied upon as the sole basis for any investment decision. While reasonable care has been taken in preparing this presentation, the Company makes no representation or warranty, express or implied, regarding the accuracy, completeness or future reliability of the information contained herein. Neither the Company nor its Directors, officers, employees or advisors shall be liable for any loss or damage arising from reliance on this presentation, except as provided under applicable law. The Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances, except as required under applicable law. Leader vision At Aptus Pharma Limited, our vision is to build a future where quality healthcare solutions are accessible, reliable, and driven by innovation. We aspire to be a globally trusted pharmaceutical organization, recognized for excellence, integrity, and sustainable growth. Our focus is on continuously strengthening our capabilities, embracing innovation, and setting new benchmarks in pharmaceutical excellence. Through a commitment to quality and responsible progress, we aim to create lasting value for patients, healthcare professionals, partners, and communities. With a future-oriented mindset, we are dedicated to shaping a healthier tomorrow—where growth is Mr. Tejash Hathi aligned with purpose, progress is guided by responsibility, and success is measured by the positive impact Managing Director we create. Driven by purpose. Defined by quality. Focused on the future. Key USPs of APPL Diversified Therapeutic Presence APPL offers a wide range of pharmaceutical, OTC and Wellness products across different therapeutic segments, helping meet various healthcare needs. Scalable Growth Strategy The company focuses on expanding its product portfolio, geographic expansion to strengthening market presence, and exploring new business opportunities for long-term growth by exploring all possible business verticals in healthcare and pharmaceutical Quality-Focused Approach APPL emphasizes maintaining high-quality standards, product safety, and consistency to deliver reliable products and build customer trust. Experienced Promoters and Professional Management The company is guided by experienced promoters and skilled professionals who contribute industry knowledge, strategic planning, and effective decision-making. Table of Contents Company Overview Business Overview Industry Overview Financial Performance Way Ahead Thank You Company Overview Aptus Pharma Ltd., established in 2010, is a fast-growing player in India's pharmaceutical sector, driven by a strong focus on brand building and market expansion. The company is engaged in developing and promoting high-quality pharmaceutical brands across diverse therapeutic segments, earning trust among healthcare professionals and consumers. Aptus partners with WHO-GMP certified manufacturers to ensure quality, scalability, and efficiency, enabling agile growth in competitive markets. With a growing presence across multiple states, the company has built a robust network of doctors, distributors, and healthcare professionals, supported by a dedicated field force. Aptus offers a diversified portfolio of 300+ formulations spanning chronic, acute, and wellness segments. Its business is strategically structured across key verticals: the Phrama Formulation Vertical, which drives core revenues through prescription-based therapies and strong doctor engagement; the OTC Vertical, focused on consumer healthcare and wellness products; and the Global Vertical, which expands international reach while contributing to revenue through exports and related service income. As a Public Limited Company listed on the BSE SME platform, Aptus Pharma Ltd. continues to strengthen its position with a vision of delivering accessible, affordable, and high-quality healthcare solutions while driving sustainable and scalable growth BUSINESS OVERVIEW 45,000+ Retail avability 300+ 250+ Distributors - Sub-Distributor H1 2026 - 27 Journey Continues Aptus Pharma continues its transition from a regional pharmaceutical company towards a broader national presence. As part of our planned expansion, we are targeting 46% geographic coverage across India by March 2027. Our long-term focus remains on strengthening our product portfolio, expanding our distribution network, developing manufacturing capabilities and exploring opportunities in international markets. Major Therapetic Solutions 01 02 03 04 05 06 07 RESPIRATORY NUTRITIONAL ANTI- ANTI-INFECTIVES ANTACIDS & PPI G.I.MEDICINES ANTI-ALLERGIC MEDICINE SUPPLEMENTS INFLAMMATORY 08 09 10 11 12 13 14 PAIN NEUROPSYCHIATRIC LIPID-LOWERING ANTI-HYPERTENSIVES & ANTIDIABETIC URO CARE CRITICAL CARE MANAGEMENT MEDICINE MEDICINE CARDIOVASCULAR MEDICINE MEDICINE 15 16 17 18 19 20 AYUSH OTC & WELLNESS SKIN CARE HAIR CARE FACE CARE ORAL CARE PRODUCTS PRODUCT PRODUCT PRODUCT INDUSTRY OVERVIEW Global Pharmaceutical Industry Global Pharmaceutical Industry Continues to Expand on Ageing Population, Chronic Diseases & Innovation ~$1.7 >$2.3 v v v Trillion Trillion Global Pharma Expected Market CAGR Market by 2030 Growth Drivers Rising ageing Increasing prevalence Healthcare spending Strong pipeline of Expansion of AI improving drug population of chronic diseases increasing globally biologics & specialty emerging markets discovery and drugs commercialization Global pharma is gradually shifting from traditional small m [Showing first 8,000 characters — download PDF for full document]